Can We Predict the High-Risk Patient?
Authors:
- Edouard LouisELEdouard Louis
- 1 June 2014
- journal article
- review article
- Published by S. Karger AG in Digestive Diseases
- Vol. 32 (4) , 328-336
Abstract
Background: While therapeutic strategies able to change the natural history of inflammatory bowel diseases (IBD) are being developed, factors predicting aggressive disease are needed to be able to choose the appropriate therapeutic strategy for the individual patient based on the risk/benefit ratio. The aim of this review is to focus on the tools assisting the clinician in routine practice regarding the prediction of disease evolution. Methods: A literature review was performed, which was mainly based on PubMed search, using the following terms: Crohn's disease, ulcerative colitis, inflammatory bowel disease, genetics, serology, biomarkers, endoscopy, C-reactive protein, faecal calprotectin, disease evolution and complications. Results: For the prediction of disease evolution, clinical characteristics, particularly disease location and behaviour, are probably currently the most useful. In addition, a series of biomarkers, including genetic, serological and inflammatory markers, as well as characteristics of endoscopic lesions may have an added value. Conclusions: Simple clinical, biological and endoscopic tools may help the clinician in predicting disease evolution in IBD. However, these tools are still insufficient, and prospective evaluation of new genetic and biological markers are needed.Keywords
This publication has 65 references indexed in Scilit:
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseNature, 2012
- Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitisJournal of Clinical Investigation, 2011
- Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)Scandinavian Journal of Gastroenterology, 2009
- Both Preoperative Perinuclear Antineutrophil Cytoplasmic Antibody and Anti-CBir1 Expression in Ulcerative Colitis Patients Influence Pouchitis Development After Ileal Pouch–Anal AnastomosisClinical Gastroenterology and Hepatology, 2008
- Family History and Serology Predict Crohn's Disease after Ileal Pouch-Anal Anastomosis for Ulcerative ColitisDiseases of the Colon & Rectum, 2008
- Diverse effects of the CARD15 and IBD5 loci on clinical phenotype in 630 patients with Crohnʼs diseaseEuropean Journal of Gastroenterology & Hepatology, 2008
- Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based CohortGastroenterology, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosisGut, 2001
- Colonoscopy of acute colitisDigestive Diseases and Sciences, 1994